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We aimed to establish the observer repeatability and interscan reproducibility of 
coronary 18F-sodium-fluoride positron emission tomography (PET) uptake using, a novel 
semi-automated approach, coronary microcalcification activity (CMA). 
Methods 
Patients with multivessel coronary artery disease underwent repeated hybrid PET and 
computed tomography angiography (CTA) imaging (PET/CTA). CMA was defined as 
the integrated standardized uptake values (SUV) in the entire coronary tree exceeding 2 
standard deviations above the background SUV. Coefficients of repeatability between 
the same observer (intraobserver repeatability), between 2 observers (interobserver 
repeatability) and coefficient of reproducibility between 2 scans (interscan 
reproducibility), were determined at vessel and patient level. 
Results 
In 19 patients, CMA was assessed twice in 43 coronary vessels on two PET/CT scans 
performed 12±5 days apart. There was excellent intraclass correlation for intraobserver 
and interobserver repeatability as well as interscan reproducibility (all ≥0.991). There 
was 100% intraobserver, interobserver and interscan agreement for the presence 
(CMA>0) or absence (CMA=0) of coronary18F-NaF uptake. Mean CMA was 3.12±0.62 
with coefficients of repeatability of ≤10% for all measures: intraobserver 0.24 and 0.22, 
interobserver 0.30 and 0.29 and interscan 0.33 and 0.32 at a per-vessel and per-patient 
level respectively. 
Conclusions 
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CMA is a repeatable and reproducible global measure of coronary atherosclerotic 
activity. 
Keywords: Motion correction, PET/CT, Cardiac PET, 18F-NaF, Vulnerable plaque, 
Coronary Microcalcification Activity
Abbreviations
CMA coronary microcalcification activity
18F-NaF 18F-sodium fluoride
PET positron emission tomography
CTA computed tomography angiography
MC cardiac motion corrected
BC background blood pool clearance correction
TBR target to background ratio
SUV standardized uptake value 
TBRMAX maximum target to background ratio
SUVMAX maximum standardized uptake value 
VOI volume of interest
BMI body-mass index
Page 8 of 72
Footer Text































































Hybrid positron emission tomography and computed tomography (PET/CT) imaging 
with 18F-sodium fluoride (18F-NaF) can be used as a marker of developing 
microcalcification across multiple different vascular and valvular disease states (1-6). It 
has been used to assess atherosclerotic disease activity in the coronary arteries, with 
the potential to identify high-risk plaques (1, 7-10). To date, most studies have reported 
coronary 18F-NaF PET uptake using maximum target to background ratio (TBRMAX) (3, 
7, 9, 11, 12). While TBRMAX has been used as the primary measure for individual 
lesions (11, 13), its measurement can vary depending on plaque activity, the anatomical 
location of the background activity measured, and the partial volume effects of such 
small structures (14, 15).  
We have developed a novel semi-automated approach to measure 18F-NaF uptake 
throughout the entire coronary vasculature. This method uses centerlines defined by 
coronary CT angiography to build 3-dimensional tubular volumes of interest around 
each of the main epicardial coronary arteries (8) and thereby derive a single summary 
measure of total coronary microcalcification activity (CMA). This method allows 
evaluation of coronary 18F-NaF activity on a per-vessel and per-patient basis, providing 
a global assessment of disease activity in the coronary arteries that is akin to the 
Agatston coronary artery calcium score for CT-defined coronary macrocalcification (8). 
CMA appears to correlate more closely with established CT-derived markers of plaque 
vulnerability than TBRMAX (9). However, the observer repeatability and interscan 
reproducibility of CMA has yet to be established. In this study, we aimed to evaluate the 
intra- and interobserver repeatability and interscan reproducibility of CMA. 
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Twenty patients underwent two 18F-NaF PET/CT examinations of the coronary arteries 
within three weeks of each other as a part of the Dual Antiplatelet Therapy to Inhibit 
Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk 
Coronary Plaque Disease (DIAMOND) Study (NCT02110303) (16). Inclusion in the 
study required angiographically confirmed multivessel coronary artery disease, defined 
by either previous revascularization or stenosis >50% in at least two major epicardial 
coronary arteries. Exclusion criteria were an acute coronary syndrome within 12 months 
prior to the examination, renal dysfunction (estimated glomerular filtration rate ≤30 
mL/min/1.73 m2) and contraindication to iodinated contrast media. This study was 
approved by the Scottish research ethics committee (REC reference: 14/SS/0089) and 
written informed consent was obtained from all participants.
Image Acquisition Protocol (PET/CT acquisition)
All patients underwent two 18F-NaF PET/CT scans within three weeks. 
PET acquisition
Patients underwent a 30-min list-mode PET-emission acquisitions approximately 1 h 
after injection of 250 MBq of 18F-NaF. All patients were scanned with arms positioned 
above the head in a 128-slice Biograph mCT system (Siemens Healthineers, Knoxville, 
TN, USA). A low-dose CT for attenuation correction was acquired immediately before 
the PET acquisition (120 kV, 50 mAs, 3-mm slice thickness). All patients were imaged 
with 3-lead electrocardiogram cardiac gating.
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For anatomical localization of PET uptake, coronary computed tomography angiography 
(CCTA) was performed immediately after the PET acquisition. The CCTA was 
performed using prospective gating, 330 ms rotation time, body-mass index (BMI) 
dependent voltage (<25 kg/m2, 100 kV; ≥25 kg/m2, 120 kV), and tube-current time 
product of 160–245 mAs. Patients were administered oral or intravenous beta-blocker 
therapy to achieve a target heartrate of <60 beats/min. A BMI-dependent bolus-injection 
of contrast media (400 mg/mL) was administered to the patients with a flow of 5–6 mL/s 




PET images were reconstructed into 4 cardiac phases using a vendor provided software 
(JS-Recon12, Siemens, Knoxville, TN, USA). All PET image reconstructions were 
performed with corrections for time-of-flight and point-spread function. Using 4 cardiac 
gates, we reconstructed the data on a 256 × 256 matrix (109 slices, slice thickness 
2.027 mm) using 2 iterations, 21 subsets and 5-mm Gaussian filter. 
Cardiac Motion correction 
Cardiac motion corrected images were obtained from the gated PET reconstructions 
through PET-PET image co-registration using a diffeomorphic registration and 
dedicated software (FusionQuant version 1.19.2.7, Cedars-Sinai Medical Center)  (17).
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Prior to image analysis, the PET reconstructions were registered to the CCTA images, 
using a rigid translation of the PET images. The PET to CCTA registration was ensured 
using five key points of reference: sternum, vertebrae, blood pool in the left and right 
ventricle (based upon high 18F-NaF activity in the blood pool in comparison to the 
surrounding myocardium), and the great vessels (18). 
Blood clearance correction 
To minimize the impact of variations in background blood pool activity introduced by the 
injection-to-scan delays (13, 19), we standardized the background blood pool activity to 
an injection-to-scan delay of 60 minutes using a previously described correction factor 
(13) (Equation 1):
SUVBackground corrected = SUVBackground*e(−0.004*(60−t)) (Equation 1)
where t represents the injection-to-scan delay in minutes.
CMA quantification  
Based upon PET image analysis techniques widely used in oncology and cardiac 
sarcoidosis (20-22) as well as the Agatston method for quantifying coronary CT calcium 
scores, we developed a novel measure  to assess whole vessel activity in the coronary 
tree (8). To obtain the CMA values, two distinct steps were performed. First, we 
selected the proximal and distal end of the vessel (>2 mm) and applied a vessel 
tracking algorithm to extract whole-vessel tubular 3D volumes of interest from CCTA 
using dedicated semi-automated Autoplaque software  (version 2, Cedars-Sinai Medical 
Page 12 of 72
Footer Text






























































Center, Los Angeles, CA)(23) (Figure 1). These encompass all the main epicardial 
coronary vessels and their immediate surroundings (4-mm radius) facilitating per-vessel 
and per-patient uptake quantification. In a tubular VOI, along the extracted centerlines, 
with 4-mm radius, we measured the CMA on the PET/CCTA co-registered images. For 
this study, we evaluated 18F-NaF activity along the entire course of coronary arteries 
regardless of the presence of coronary stents, and we included the left main in the left 
anterior descending artery VOI. To avoid overspill of aortic root activity (spill-over 
effects), we excluded coronary activity in the orifice of the left main stem of being 
incorporated in the analysis. CMA was defined as the average SUV within the activity 
volume above threshold of background SUV mean +2 standard deviations. The 
background activity was measured in the right atrium. 
TBRMAX quantification 
CTA studies were assessed visually for percent stenosis according to the Society of 
Cardiovascular Computed Tomography guidelines (24). For a signal to be co-localized 
to a coronary artery, an atherosclerotic plaque had to be present on CT angiography, 
and the increased pattern of radiotracer had to arise from the coronary artery and follow 
its course over >5 mm in three dimensions on orthogonal views (25). On the co-
registered PET and CTA images, 18F-NaF PET uptake was measured in all coronary 
segments with a vessel diameter ≥2 mm and >25% stenosis as defined by CTA. The 
18F-NaF uptake in these lesions was evaluated in a 3D spherical volume of interest 
(VOI) (radius 5 mm). In all plaques meeting these criteria, the maximum standardized 
uptake values (SUVMAX) were measured within manually drawn regions of interest. 
TBRMAX values were calculated by dividing the coronary SUVMAX by the blood pool 
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activity measured in the right atrium (cylindrical volume of interest radius 10 mm and 
thickness 5 mm) at the level of the right coronary artery ostium. 
Diagnostic Evaluation of CMA and TBRMAX 
Using CMA, the individual coronary arteries were marked as 18F-NaF positive if CMA>0 
and negative if CMA =0 (8). We also assessed the burden of activity on a per-vessel 
and per-patient level. To allow a per-patient analysis, we added the CMA activity of all 
major epicardial vessels (CMAtotal).  For TBR, PET uptake was quantified based on the 
CCTA lesion position, with lesions categorized as 18F-NaF-positive (TBRMAX ≥1.25) or 
18F-NaF-negative (TBRMAX <1.25) (3, 7, 26). In order to compare TBRMAX with CMA, we 
plotted the percentage differences in Bland-Altman plots.
Observer Repeatability and Interscan Reproducibility 
Two anonymized scans for each of the 20 patients were presented to 2 experienced 
observers in random order.  First, repeat assessments (observations 1 & 2) were 
performed by observer 1 at least 12 weeks apart in random order to prevent recall bias 
(intraobserver repeatability). Secondly, a second observer (observer 2) performed 
analysis for both scans and we compared them with measurements performed by the 
first observer (interobserver repeatability). Lastly, we compared the measurements 
between baseline scan (scan1) and repeat scan 2-3 weeks later (scan 2) in order to 
compute the interscan reproducibility. 
Statistical analysis
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Data were tested for normality using the Shapiro–Wilk test. Statistical analysis was 
performed using MedCalc Statistical Software version 16.4.3 (MedCalc Software, 
Ostend, Belgium). Continuous, normally distributed variables were presented as mean ± 
standard deviation, whereas non-normally distributed continuous data were presented 
as median [range]. Assessment of CMA and TBRMAX, observer repeatability and 
interscan reproducibility were obtained using descriptive statistics with intraclass 
correlation coefficient (ICC) as well as Bland–Altman plots with mean bias and limits of 
agreement (LOA). 
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Twenty patients were recruited (Table 1), although one patient was excluded from the 
study due to incomplete list mode PET data. From the 57 coronary arteries included in 
the study, a total of 49 vessels fitted the size criterion (>2 mm in diameter). We 
excluded 6 vessels from the analysis: all vessels were the left circumflex coronary artery 
and were excluded due to spillover of 18F-NaF activity from neighboring mitral valve 
calcification (3 from scan 1 and 3 from scan 2), leaving a total of 43 vessels for the final 
analysis. A total of 47 lesions were identified on CCTA in these 43 vessels. The mean 
uptake values observed for the two readers and the repeated scans were 3.12± 0.62 for 
CMA and 1.62±0.49 for TBRMAX. 
Presence or absence of 18F-NaF activity
There was 100% intraobserver, interobserver and interscan agreement for the presence 
of 18F-NaF activity (CMA>0) or absence of 18F-NaF activity (CMA=0) (Table 2). In 
addition, there were excellent intraclass correlations between the same observer, 
different observers and between scans (all intraclass correlation coefficient (ICC) >0.99, 
Table 3). 
Intraobserver analysis 
There was excellent intraobserver repeatability for CMA measurement on a per-vessel 
level, with a coefficient of repeatability of 0.24, mean bias of −0.02 (p=0.39) and narrow 
limits of agreement (95% LOA −0.25 to 0.22; Figure 2A). Similarly, at a patient level, 
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CMAtotal repeatability coefficient was 0.22 with a mean bias of −0.03 (p=0.12) and 
narrow limits of agreement (95% LOA −0.25 to 0.18; Figure 2B). 
Interobserver analysis 
Comparable to the intraobserver analysis, there was also excellent interobserver 
repeatability for CMA measurement on a per-vessel level, with a coefficient of 
repeatability of 0.30, mean bias of −0.01 (p=0.79) and narrow limits of agreement (95% 
LOA −0.31 to 0.29; Figure 3A). At a patient level, CMAtotal repeatability coefficient was 
0.29 with a mean bias of −0.04 (p=0.17) and narrow limits of agreement (95% LOA 
−0.33 to 0.25; Figure 3B). 
Interscan analysis 
Similar to the interobserver analysis, interscan analysis of CMA showed very good 
reproducibility. At a vessel level, there was excellent interscan reproducibility with a 
coefficient of reproducibility of 0.33, mean bias of 0.02 (p=0.89) and narrow limits of 
agreement (95% LOA −0.31 to 0.35; Figure 4A). Likewise, at a patient level, CMAtotal 
reproducibility coefficient was 0.32 with a mean bias of −0.02 (p=0.30) and narrow limits 
of agreement (95% LOA −0.34 to 0.28; Figure 4B). 
CMA and TRBMAX
The activity of separate lesions (n=47) was assessed using maximum target-to-
background ratio (TBRMAX. Compared to TBRMAX, CMA showed superior limits of 
agreement and smaller coefficients of repeatability for intraobserver and  interobserver 
analysis, as well as smaller coefficient of reproducibility for interscan analyses. Between 
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the same observer, CMA showed a mean bias and limits of agreement of 0.2% (95% 
LOA -10.6 to 11.1%) and TBRMAX showed a bias of -2.4% (95% LOA -20.7 to 15.9%) 
with coefficients of repeatability of 10.8% and 18.3% respectively (Supplement Figure 
1). Similarly, between different observers, CMA  was more reproducible than TBRMAX 
with a mean bias and limits of agreement of -0.1% (95% LOA -14.1 to 4.0) and -3.75% 
(95% LOA -25.2% to 17.8%) respectively and coefficients of repeatability of 14.0% and 
19.5% (Supplement Figure 2). Finally, between scans, CMA showed a mean bias and 
limits of agreement of 0.1% (95% LOA -17.4 to 17.2%) and TBRMAX showed a bias of 
0.3% (95% LOA -24.0% to 24.6%) with coefficients of reproducibility of 17.2% and 
24.3% respectively (Supplement Figure 3).
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Coronary 18F-NaF PET is a non-invasive tool for imaging vulnerable atherosclerotic 
plaques (7, 8). We evaluated the repeatability and reproducibility of a novel 
methodology (CMA) for assessing whole vessel coronary 18F-NaF uptake on PET/CT as 
a single measure of patient risk (8). We showed that CMA has excellent intra- and 
interobserver repeatability and interscan reproducibility and narrow limits of agreements 
within and between scans. This suggests that CMA is sufficiently robust to be used as 
single measure of coronary atherosclerotic activity and has the potential to provide a 
summary score of coronary risk similar to that described by the Agatston coronary 
artery calcium score (27).  
It is now widely accepted that the anatomic assessment of the whole-coronary disease 
burden (vulnerable patient) is of greater importance than the identification of a single 
vulnerable plaque (28-30). We have shown that both TBRMAX and CMA assessments 
were repeatable and reproducible, albeit CMA had the best repeatability and 
reproducibility. This has important implications for serial scanning and monitoring 
disease progression with coronary PET. Furthermore, there was no diagnostic 
discordance between observers or scans for CMA, something that is not always true for 
TBRMAX. For the presence of 18F-NaF activity (CMA>0) or absence of activity (CMA=0), 
there was 100% agreement in the categorization between observers or scans with no 
crossover of cases observed (Table 2). On the other hand, there were 3 discordant 
values for TBRMAX between observers and 4 discordant values between scans. This is 
of high importance in populations without known coronary artery disease if 18F-NaF is to 
be used as a screening tool where little or no activity is expected. In such population the 
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fact that CMA=0 is reproducible between observers and scans is of extreme importance 
as it could reassure the physician.
This is the first study investigating the repeatability and interscan reproducibility of both 
CMA and TBRMAX. In a previous study (11), we showed that TBRMAX displayed good 
observer repeatability and interscan reproducibility when employing mid-diastolic PET 
images. This can be further improved using cardiac motion-corrected reconstructions 
(13). However, we have here reported narrower limits of agreement for observer 
repeatability and interscan reproducibility, both at a vessel as well as at a patient level. 
Another strength of CMA is that it integrates the total activity of all 3 vessels in a score 
that resembles the well-established calcium score; i.e. a patient with CMA= 0 has no 
active microcalcification similar to a patient with zero calcium score. Unlike TBR, CMA 
measures patient-level total 18F-NaF activity burden assessment and hence does not 
rely on a single hot pixel-value leading to better reproducibility. Furthermore, by 
identifying the coronary artery borders from CTA and limiting the assessment of 18F-NaF 
uptake within these borders, the CMA approach has the strength to reduce the 
subjectivity and the time required to perform image analysis. 
Despite the broad application of the individual lesion assessments using TBRMAX (3, 7, 
9, 11-13, 25, 30), this technique can only provide an estimation of activity at an 
individual plaque level, and as a result, the overall coronary disease burden of active 
macrocalcification cannot be appreciated. Indeed, this approach bears the risk of 
underestimating the 18F-NaF activity in patients with multiple plaques with increased 
tracer activity across the coronary tree (Figure 5). Using CMA, and computing the total 
activity burden, we were able to translate 18F-NaF PET tracer uptake into the total 
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coronary macrocalcification activity mirroring an approach successfully applied in the 
field of oncology and cardiac sarcoidosis (metabolic activity volume) (20-22). Thus, 
CMA provides a measure of the overall burden of disease activity for the patient.
Finally, despite the excellent prognostic information that coronary calcium scoring 
provides in asymptomatic individuals (31, 32) and those presenting with chest pain (33), 
its prognostic capability has been suboptimal in studies involving patients with 
established advanced coronary artery disease (34, 35). While coronary calcium 
visualizes advanced and potentially healed disease (macrocalcification), it lacks the 
ability to visualize active disease (microcalcification) or predict future calcification 
progression. On the other hand, 18F-NaF uptake is associated with culprit coronary 
plaques in patients with myocardial infarction (7), adverse plaque features in patients 
with apparently stable disease (9) and predicts the future progression of coronary 
calcium scores, confirming its status as a marker of disease activity (36). In addition, in 
a small study involving 32 patients, Kitagawa et al (12) showed that higher 18F‐NaF 
uptake in established coronary atherosclerotic lesions on PET has  a predictive value 
for future cardiac events (acute coronary syndrome or late coronary revascularization) 
that was superior to the predictive value of the findings on CCTA, including coronary 
artery stenosis, high risk plaques and calcification. Moreover our group has recently 
shown, in a large multicohort study involving 293 patients with established multivessel 
coronary artery disease, that CMA outperforms coronary calcium score in prediction of 
myocardial infarction and major adverse cardiovascular events (MACE) (37). 
Limitations
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This study has several additional limitations; first is the number of patients included in the 
study (19). Despite the low number of participants, we were able to identify 47 separate 
lesions and we have evaluated each patient both at a per-vessel level  and per-patient 
level. Another limitation was that we used only cardiac motion corrected images and did 
not apply gross patient motion and respiratory motion corrections (triple motion 
corrections)(13). The third limitation of this study was that all lesions were manually 
delineated by only two expert readers which may affect its broader generalizability. 
Finally, this study was obtained in a single center using a PET/CT system from one vendor 
only. A bigger multicenter study including systems from multiple vendors would be 
required to confirm our findings. 
New Knowledge Gained
Using CMA provides an accurate and highly reproducible metric of 18F-NaF PET/CT 
uptake. This finding is important to ensure the optimal quantitative accuracy in studies 
utilizing 18F-NaF, such as PREFFIR [NCT02278211](11), a study involving 700 patients 
with multi-vessel coronary artery disease. Based on this finding and given the 
comparable reproducibility of ΤΒRMAX, both approaches can be implemented in future 
clinical trials. 
Conclusion
In conclusion, we have shown CMA provides a novel metric of the per-vessel and per-
patient coronary 18F-NaF PET activity that has excellent intraobserver, and 
interobserver repeatability and interscan reproducibility. We suggest that CMA could be 
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used as a global patient level measure of 18F-NaF uptake with potential application to 
clinical trials and clinical practice.
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Age (years) 70 ± 8
Gender (males) 16 (84)
Body-mass index (kg/m2) 27.6 ± 4.0
Cardiovascular risk factors
- Diabetes mellitus (type II) 2 (11)
- Current smoker 2 (11)
- Hypertension 13 (68)
- Hyperlipidemia 19 (100)
Agatston Calcium Score (AU) 1075 [0-1890]
Continuous variables reported as mean ± SD or median and 
interquartile range [IQR]; categorical variables reported as n (%), 
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Intraobserver (A), interobserver (B) and interscan (C) variability for the presence or the 
absence of 18F-sodium fluoride uptake (coronary microcalcification activity) at a vessel 
level (n=43). 
Observation* 2 Observation* 2
CMA>0 CMA=0 TBRMAX≥1.25 TBRMAX<1.25









CMA=0 0 9 TBRMAX<1.25 1 12
Observer 2 Observer 2







CMA=0 0 9 TBRMAX<1.25 2 12
Scan 2 Scan 2





CMA=0 0 9 TBRMAX<1.25 2 13
CMA: Coronary Microcalcification Activity, TRBMAX: maximum target to background ratio 
*Observations 1 and 2 were performed by Observer 1 at least 12 weeks apart in random 
order to prevent recall bias. 
Page 28 of 72
Footer Text































































Intraclass correlation coefficient (ICC) for intraobserver and interobserver repeatability 
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Three-dimensional rendering of coronary computed tomography (CT) angiography with 
superimposed tubular whole vessel volumes of interest (light green) employed for 
evaluation of 18F-sodium fluoride (18F-NaF) positron emission tomography (PET) uptake 
(blue and red). Despite the relatively low maximum tissue-to-background ratio (TBRMAX) 
due to multiple foci of increased 18F-NaF activity, the coronary microcalcification activity 
(CMA) in the right coronary artery (RCA) is higher than in the left anterior descending 
(LAD) coronary artery which presented with a higher TBRMAX (LCx= Left circumflex 
artery).
Figure 2 
Intraobserver repeatability of coronary microcalcification activity at vessel (A) and 
patient (B) level. [CMA: coronary microcalcification activity, SD: standard deviation, CR: 
Coefficient of repeatability]
Figure 3
Interobserver repeatability of coronary microcalcification activity at vessel (A) and 
patient (B) level. [CMA: coronary microcalcification activity, SD: standard deviation, CR: 
Coefficient of repeatability]
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Interscan repeatability of coronary microcalcification activity at vessel (A) and patient (B) 
level. [CMA: coronary microcalcification activity, SD: standard deviation, CR: Coefficient 
of reproducibility]
Figure 5 
Paired coronary tomography images (CT) and fused positron emission tomography 
(PET) /CT images of a representative patient with multiple lesions across the coronary 
tree assessed by two observers and with repeated scans. Panel (A) shows the right 
coronary artery (RCA) with multiple plaques across the length of the artery and 
respective 18F-NaF PET uptake. Tubular whole vessel volumes of interest (light green) 
employed for evaluation of 18F-NaF (PET) uptake (bright yellow to red), B) Left main 
stem and left anterior descending artery (LMS/LAD) with multiple plaques and 18F-NaF 
PET uptake and C) left circumflex (LCx) with a calcified proximal plaque and uptake.
[CMA: coronary microcalcification activity, TRBMAX: maximum target to background 
ratio]
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